folate receptor α

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (Ki: 6.5 nM). It also has antitumor activity.

EC0489, Small molecule-drug conjugate (SMDC) ,a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor.

The peak excitation and emission wavelengths of EC-17 are 470/520 nm.EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum.

Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is an orally active and effective thymidylate synthase (TS) inhibitor (Ki: 0.44 nM). Plevitrexed is used for gastric cancer in clinical.

ONX 0801 (BGC 945) trisodium is a targeted thymidylate synthase (TS) inhibitor specifically designed to act against tumors overexpressing the α-folate receptor.

BGC-638, an analogue of BGC-945, is a thymidylate synthase inhibitor specifically transported into α-folate receptor (α-FR)–overexpressing tumors.

Farletuzumab (MORAb-003) 是一种有效的叶酸受体-α (FRα) 抑制剂。Farletuzumab 是一种对 FRα 具有高亲和力的人源化单克隆抗体。Farletuzumab 抑制过表达 FRα 的细胞的生长。Farletuzumab 可用于研究癌症。

Mirvetuximab (M9346A) 是一种新型叶酸受体α (FRα) 靶向 anti-FOLR1 (folate receptor 1) 的单克隆抗体。Mirvetuximab soravtansine 常与铂类化合物或与其他化合物偶联成为抗体-药物偶联物用来治疗卵巢癌和其他 FRα 阳性的癌症。

Mirvetuximab soravtansine (IMGN853) 是一种靶向叶酸受体α （FRα） 的抗体-药物偶联物（ADC），抑制细胞生长，增强 DNA 损伤的抗增殖效果，可用于研究耐药卵巢癌。

Farletuzumabecteribulin（MORAb-202）是一款人源化抗人叶酸受体α（FRA）抗体Farletuzumab与Mal-PEG2-Val-Cit-PAB-eribulin通过还原的链间二硫键偶联成的抗体-活性分子偶联物（ADC）。该化合物活性分子抗体比率为4.0，对FRA阳性细胞展示出强大的体外细胞毒性，并具备有效的抗肿瘤活性。

FRα-targeting peptide C7, 作为一种选择性的叶酸受体α (FRα) 肽配体，展现出对FRα表达细胞的特异性结合及其在体内对肿瘤的靶向能力。该配体在肿瘤诊断与治疗领域的研究中具有应用潜力。

FRα-targeting peptide C7 TFA 是一种选择性肽配体，专门与叶酸受体α (FRα) 表达细胞结合，并具有在体内实现肿瘤靶向的能力。FRα-targeting peptide C7 TFA 可用于研究肿瘤的诊断和治疗。